Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie Inc. ABBV, -1.86% said Friday it had net income of $3.010 billion, or $2.02 a share, in the first quarter, up from $2.456 billion, or $1.65 a share, in the year-earlier period.

AbbVie tops earnings estimates, sticks with 2020 guidance

AbbVie earnings and sales topped first-quarter views. The drug giant's stock edged higher.

AbbVie Earnings Top; Drug Giant Edges Higher

AbbVie's (ABBV) Q1 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.

Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q1 Earnings?

GlaxoSmithKline

Johnson & Johnson

Johnson & Johnson, AbbVie, and GlaxoSmithKline are all good choices.

3 Healthcare Stocks With Solid Dividends to Hold Through Bumpy Times

Ford Motor Company

Valero Energy

Wells Fargo

4 Picks For Uncertain Times

AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

Brookfield Infrastructure Partners L.P.

AT&T

3 Dividend Stocks Yielding More Than 5% That Are Safe Buys Right Now

Allergan

The coronavirus has completely changed the narrative on AbbVie’s buyout of AGN. Allergan stock holders banking on it should reconsider.

The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors

ABBV stock does not fully reflect the deep pipeline of drugs under development and the billions in future sales from two key drugs.
The post Why You Can Buy AbbVie At a Massive Discount appeared first on InvestorPlace.

Why You Can Buy AbbVie At a Massive Discount

Charter Communications

Tesla

Short sellers have anywhere from $4.5 billion to $14.4 billion bet against these well-known companies.

Wall Street's 3 Most-Hated Stocks

Myovant Sciences

With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.

Myovant Squares Off with AbbVie On Endometriosis Treatment

Brookfield Renewable Partners

These stocks offer high dividend yields and solid businesses.

3 Dividend Stocks I'd Buy Right Now: ABBV, BEP & BIP

Amgen

Novartis

These three stocks aren't just surviving the coronavirus storm -- they're thriving in it.

3 Dividend Stocks Weathering the Coronavirus Storm

Gilead Sciences

Revenue growth is on the horizon for both stocks, but one offers a better buying opportunity right now.

Better Buy: AbbVie vs. Gilead Sciences

The cancer drug is now approved for 11 different indications.

Johnson & Johnson and AbbVie Earn a New FDA Approval for Imbruvica

Pfizer

AbbVie and Pfizer are rock-solid dividend stocks.

2 Best Dividend Stocks to Buy Now

AbbVie's (ABBV) regulatory application seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan gets approval from the FDA.

AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL

Bunge Global SA

Chevron

DXC Technology

Nu Skin Enterprises

Patterson Companies

Steep market declines in 2020 have not only been brutal on returns; they've also presented income investors with a conundrum.

8 Safe High-Yield Dividend Stocks Offering 5% or More

3 Dividend Stocks  I'd Buy Right Now

With a major acquisition in the works, ABBV stock isn't just a dividend king, but a rapidly-diversifying juggernaut.
The post Buy AbbVie Stock as the Drugmaker Diversifies Its Pipeline appeared first on InvestorPlace.

Buy AbbVie Stock as the Drugmaker Diversifies Its Pipeline

AbbVie Inc (NYSE: ABBV) shares already discount much of the risk emanating from the COVID-19 crisis, according to an analyst at RBC Capital Markets.

AbbVie Analyst Upgrades Stock To Outperform, Looks Forward To 2021

High dividend yields plus solid businesses make these stocks great picks for retirees.

3 Stocks to Supplement  Your Social Security Income

Automatic Data Processing

Emerson Electric

Federal Realty Investment Trust

General Dynamics

Lowe's

Medtronic

Altria

Parker-Hannifin

Raytheon Technologies

Stanley Black & Decker

T. Rowe Price Group

Last week the S&P 500 had its best week since 1974, roaring higher by 12%. That defies the mounting economic damage the US is facing and plummeting earnings expectations.

The 13 Best Dividend Aristocrats To Buy In This Uncertain Economy

AbbVie Inc.: The Opportunity, The Risks

AbbVie: Powerful R&D Portfolio Backing Strong Shareholder Returns

News for AbbVie Stock (ABBV)